More News

21 Nov 2016 Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
19 Nov 2016 Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates
17 Nov 2016 Bellicum Pharmaceuticals Recommended for $16.9 Million Award from the Cancer Prevention and Research Institute of Texas
16 Nov 2016 Genexine Enters into Clinical Research Collaboration with MSD
16 Nov 2016 Sorrento's TNK Therapeutics Subsidiary to Acquire Virttu Biologics
16 Nov 2016 Integrated BioTherapeutics, Inc. Announces Licensing Agreement with Emergent BioSolutions for Development of Equine Immunoglobulin Therapeutics for Filovirus Infections
16 Nov 2016 Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
15 Nov 2016 Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
15 Nov 2016 uniQure completes stratetic review to refocus its pipeline, reduce operating costs and deliver long-term shareholder value
15 Nov 2016 Neovacs acquires interferon alpha manufacturing technology from Amegabiotech
10 Nov 2016 Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research
10 Nov 2016 Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
10 Nov 2016 Cell Medica and Baylor College of Medicine Expand Partnership to Develop Allogeneic CAR-NKT Cells for Cancer Treatment
10 Nov 2016 Sosei Subsidiaries Heptares and Jitsubo to Develop Novel GPCR-Targeting Peptide Candidates for Severe Gastro-Intestinal Disorders
09 Nov 2016 Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors
09 Nov 2016 DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform
09 Nov 2016 The Center for iPS Cell Research and Application at Kyoto University (CiRA), Takeda and Yokohama City University enters a Joint Research Agreement on an iPS Cell Research Project
08 Nov 2016 AdAlta Licenses Alzheimer's Disease-Specific Shark Antibodies to Crossbeta Biosciences for Therapeutic and Diagnostic Development
07 Nov 2016 Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb
07 Nov 2016 Axiogenesis and Metrion Biosciences announce stem cell collaboration
07 Nov 2016 AdAlta and XL-protein Announce Collaboration to Develop a Long Acting Version of Its Lead Fibrosis Drug Candidate AD-114 Using PASylation® Technology
07 Nov 2016 Actelion to provide an update on advancements in its cardiovascular pipeline in PAH and beyond
06 Nov 2016 Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
04 Nov 2016 EnBiotix Acquires Anti-Microbial Peptide Portfolio from AMP Therapeutics GmbH
04 Nov 2016 Selexis and Xencor Enter Strategic Agreement, Strengthening Existing Relationship for Multi-Specific Antibody Cell Line Development

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top